Erlotinib: A pharmacoeconomic review of its use in advanced non-small cell lung cancer

PharmacoEconomics

Volumn 28, Issue 1, 2010, Pages 75-92

  Lyseng Williamson, Katherine A ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB;

ANTINEOPLASTIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; HUMAN; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY; OVERALL SURVIVAL; PHARMACOECONOMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BUDGETS; CARCINOMA, NON-SMALL-CELL LUNG; COST CONTROL; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; MODELS, ECONOMIC; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINES;

EID: 73449117924     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/10482880-000000000-00000     Document Type: Review

References (53)

1. European Medicines Agency. Tarceva (erlotinib): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ tarceva/emea-combined-h618en.pdf [Accessed 2009 Aug 3]
2. Tarceva (erlotinib): US prescribing information. South San Francisco (CA): Genentech USA, Inc, 2009 Apr
3. Robinson D, Keating G, Perry C. Erlotinib. Am J Cancer 2005; 4 (4): 247-252
4. Dancey JE. Epidermal growth factor receptor inhibitors in non-small cell lung cancer. Drugs 2007; 67 (8): 1125-1138
5. Perez-Soler R. Erlotinib: recent clinical results and ongoing studies in non-small cell lung cancer. Clin Cancer Res 2007 Aug 1; 13 (15 Suppl.): 4589s-92s
6. Gridelli C, Ardizzoni A, Ciardiello F, et al. Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol 2008 Apr; 3 (4): 430-440
7. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol 2009 May; 20 Suppl. 4: iv68-70
8. Felip E, Garrido P, Trigo JM, et al. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin Transl Oncol 2009 May; 11 (5): 284-289
9. National Comprehensive Cancer Network®. NCCN Clinical Practice Guideline in Oncology: non-small cell lung cancer. V.2.2009 [online]. Available from URL: http://www. nccn.org/professionals/physician-gls/PDF/nscl.pdf [Accessed 2009 Aug 3]
10. European Medicines Agency. Committee for medicinal products for human use: summary of positive opinion for Iressa (gefitinib) [online]. Available from URL: http://www. emea.europa.eu/pdfs/human/opinion/Iressa-20075609en.pdf [Accessed 2009 Aug 3]
11. Iressa® (gefitinib tablets): US prescribing information. Wilmington (DE): AstraZeneca Pharmaceuticals LP, 2005 Jun
12. American Cancer Society. Global cancer facts and figures 2007 [online]. Available from URL: http://www.cancer. org/downloads/STT/Global-Facts-and- Figures-2007- rev2.pdf [Accessed 2009 Aug 10]
13. American Cancer Society. Cancer facts and figures 2008 [online]. Available fromURL: http://www.cancer.org/downloads/ STT/2008CAFFfinalsecured.pdf [Accessed 2009 Aug 10]
14. Molinier L, Combescure C, Chouaid C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 2006; 24 (7): 651-659
15. Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst 2008 Dec 17; 100 (24): 1763-1770
16. Yabroff KA, Bradley CJ,Mariotto AB, et al. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008 Dec 17; 100 (24): 1755-1762
17. Ramsey SD, Martins RG, Blough DK, et al. Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008 May; 14 (5): 297-306
18. Pompen M, Gok M, Novák A, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in the Netherlands. Lung Cancer 2009 Apr; 64 (1): 110-116
19. Fox KM, Brooks JM, Kim J.Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manage Care 2008 Sep; 14 (9): 565-571
20. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Pharmacoeconomics 2001; 19 (8): 855-863
21. Nafees B, Stafford M, Gavriel S. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008 Oct 21; 6: 84
22. Tabberer M, Stamuli E,Walker M, et al. Utilities associated with non-small cell lung cancer (NSCLC): a community study [abstract no. PCN74]. Value Health 2006; 9 (6): A298
23. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 Jul 14; 353 (2): 123-132
24. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006 Aug 20; 24 (24): 3831-3837
25. Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 May 10; 26 (14): 2350-2357
26. Zhu C-Q, da Cuhna Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008 Sep 10; 26 (26): 4268-4275
27. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007 Jul 1; 13 (13): 3913-3921
28. Araú jo A, Parente B, Sotto-Mayor R, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14 (6): 803-827
29. Batigun O, Yildirim E. Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer in Turkey [abstract no. PCN77]. Value Health 2007; 10 (6): A234
30. ChenW, Sheng F, QiaoN. Cost-effectiveness of erlotinib in the treatment of advanced non small cell lung cancer in China [abstract no. PCN104]. Value Health 2009 Oct; 12 (7): A276
31. Côté I, Leighl NB, Gyldmark M, et al. Pharmacoeconomic analyses of erlotinib compared with best supportive care for the treatment of relapsed non-small cell lung cancer from the Canadian public health care perspective [abstract no. PCN11]. Value Health 2006 Nov-Dec; 9 (6): A279. Plus poster presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2006 Oct 28-31; Copenhagen
32. Hsia T, Chang G, Chen YM, et al. Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan [abstract no. PCN10]. Value Health 2007 Nov-Dec; 10 (6): A325
33. Lewis G, Morlotti L, Creeden J, et al. Cost-effectiveness of erlotinib compared with docetaxel for the treatment of relapsed non-small cell lung cancer in the UK [abstract no. CN4]. Value Health 2006 Nov-Dec; 9 (6): A203-4. Plus slide presentation at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2006 Oct 28-31; Copenhagen
34. Orlewska E, Szczesna A, Szkultecka-Debck M. Cost effectiveness of erlotinib as second line agent in the treatment of advanced non small lung cancer in Poland [in Polish]. Farmakoekonomika 2006; 10 (3): 3-16
35. Pompen M, Novak A, Gok M, et al. Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care in NSCLC [abstract no. PD6-3-5]. J Thorac Oncol 2007 Aug; 2 (8 Suppl. 4): S433
36. Rubio Terré s C, Alvarez Sanz C, Gylmark MG. Pharmacoeconomic analysis in Spain of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small cell lung cancer who have failed previous chemotherapy regimens [abstract no. PCN26]. Value Health 2006 Nov-Dec; 9 (6): A283-4. Plus poster presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2006 Oct 28-31; Copenhagen
37. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008; 61 (3): 405-415
38. van der Hoek K, Taylor SC, Peacock S, et al. Costeffectiveness analysis (CEA) of third-line erlotinib therapy compared to best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC) [abstract no. 7678]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl. Pt I): 428s
39. Bradbury PA, Jang R, Isogai P, et al. A cost utility analysis of erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC) [abstract no. PCN58]. Value Health 2008; 11 (3): A72
40. Capri S, Morabito A, Carillio G, et al. Economic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer [in Italian]. Pharmacoeconomics Ital Res Articles 2007; 9 (2): 113-124
41. Kotowa W, Gatzemeier U, Pirk O, et al. A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. JMed Econ 2007; 10 (3): 255-271
42. Stefani SD, Saggia MG, Vicino dos Santos EA. Costminimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective. J Med Econ 2008; 11 (3): 383-396
43. Orlewska E, Szczesna A, Szkultekca-Debek M. Budget impact analysis of non-small cell lung carcinoma (NSCLC) treatment with erlotinib in Polish setting [abstract no. PCN21]. Value Health 2009 May; 12 (3): A39-40
44. Ramsey SD, Clarke L, Kamath TV, et al. Evaluation of erlotinib in advanced non-small cell lung cancer: impact on the budget of a U.S. health insurance plan. J Manag Care Pharm 2006 Jul-Aug; 12 (6): 472-478
45. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 May; 18 (10): 2095-2103
46. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22 (9): 1589-1597
47. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [published erratum appears in J Clin Oncol 2004 Jan 1; 22 (1): 209]. J Clin Oncol 2000 Jun; 18 (12): 2354-2362
48. Oanda.com. FXConverter results: currency converter for 164 currencies [online]. Available from URL: http://www. oanda.com/convert/classic [Accessed 2009 Aug 20]
49. Groen H, Arrieta OG, Riska H, et al. The global TRUST study of erlotinib in advanced non-small-cell lung cancer (NSCLC) [abstract no. 19000]. J Clin Oncol 2008 May 20; 26 (15 Suppl. Pt I): 706s
50. Hoffman-La Roche. A study of Tarceva (erlotinib) and standard of care chemotherapy in patients with advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [Clinical Trials.gov identifier NCT00556322] [online]. Available from URL: http://www.clinicaltrials. gov [Accessed 2009 Aug 26]
51. Carlson J,Garrison L, Ramsey S, et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor guided therapy in nonsmall- cell lung cancer. Value Health 2009; 12 (1): 20-27
52. Bradbury PA, Tu D, Seymour L, et al. Impact of clinical and molecular predictors of benefit for erlotinib in advanced non-small cell lung cancer on cost-effectiveness [abstract no. 6531]. J Clin Oncol 2008 May 30; 26 (15 Suppl. Pt I): 344s
53. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Aug 26]